ArticlePharmaceutics2022
The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.
Dina Baier et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this papercites it